



Cite this: *RSC Adv.*, 2024, 14, 8260

# An antiviral oligomerized linear thiopeptide with a nitrile group from soil-derived *Streptomyces* sp. CPCC 203702†

Zhe Guo,<sup>‡a</sup> Dewu Zhang,<sup>‡\*a</sup> Yujia Wang,<sup>b</sup> Jinglin Bai,<sup>ab</sup> Jun Hu,<sup>a</sup> Shan Cen<sup>b</sup> and Liyan Yu<sup>\*ab</sup>

Received 27th February 2024

Accepted 5th March 2024

DOI: 10.1039/d4ra01496k

rsc.li/rsc-advances

A new linear thiopeptide, bernitrilecin (**1**), was isolated from *Streptomyces* sp. CPCC 203702. Compound **1** is the first example of a nitrile-bearing thiopeptide. Its structure and absolute configuration were elucidated by extensive analysis of spectroscopic data and Marfey's method. The biosynthesis of the nitrile unit for **1** was proposed to be through oxidations, decarboxylation, and dehydration. Compound **1** exhibited significant anti-influenza A virus activity with the IC<sub>50</sub> value of 16.7 μM.

## Introduction

Thiopeptides or thiazolyl peptides are a family of ribosomally synthesized and post-translationally modified peptide (Ripp) natural products, which are characterized by structural features including thiazole and/or oxazole rings with highly modified amino acids. Thiopeptide antibiotics are potent inhibitors of protein synthesis in Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* spp. (VRE), and penicillin-resistant *Streptococcus pneumonia* (PRSP).<sup>1–5</sup> In recent years, more biological activities of thiopeptide antibiotics such as anticancer, antiviral, immunogenic, and anti-malaria activities were reported by medicinal chemists and pharmacologists.<sup>5–10</sup> Structurally, most thiopeptides commonly feature a macrocyclic framework (cyclic thiopeptide). According to the size of the macrocycle core, thiopeptides can be divided into four classes: 26-membered, 29-membered, 32-membered, and 35-membered, which were assembled by over ten amino acids. However, there are few reports regarding linear thiopeptides. In particular, oligomerized linear thiopeptide assembled by less than ten amino acids are even rarer.<sup>1,5</sup>

Our previous chemical investigation of *Streptomyces* sp. CPCC 203702 afforded four new thiopeptides with potent antiviral activities.<sup>11</sup> As part of our ongoing search for

bioactive thiopeptide from this strain, the extracts of *Streptomyces* sp. CPCC 203702 were further investigated, leading to the isolation of a new oligomeric linear thiopeptide, bernitrilecin (**1**) (Fig. 1), which was assembled by seven amino acids. Compound **1** is the first example of a thiopeptide with a nitrile group. In this article, we report the fermentation, isolation, structural elucidation, and biological activity of bernitrilecin (**1**).

## Results and discussion

Bernitrilecin (**1**) was isolated as white amorphous powder. Its molecular formula was determined as C<sub>22</sub>H<sub>22</sub>N<sub>8</sub>O<sub>6</sub>S by HRESIMS with *m/z* 527.1451 [M + H]<sup>+</sup>, requiring 16 degrees of unsaturation. The <sup>13</sup>C NMR and DEPT data (Table 1) of **1** revealed the presence of 22 carbons, including thirteen non-protonated carbons (δ<sub>C</sub> 168.7, 165.8, 164.7, 160.1, 160.1, 160.0, 150.5, 150.3, 134.1, 133.5, 130.5, 128.3, and 116.6), six methine carbons (δ<sub>C</sub> 139.8, 129.0, 128.5, 125.8, 66.8, and 58.8), one methylene carbons (δ<sub>C</sub> 103.4), and two methyl carbons (δ<sub>C</sub> 19.8 and 13.3). The <sup>1</sup>H NMR and HSQC data (Table 1) of **1** showed 22 protons, including six sp<sup>2</sup> proton (δ<sub>H</sub> 8.86, 8.70, 8.50, 6.57, 6.47, and 5.86). In the HMBC spectrum, the cross peaks from terminal –NH<sub>2</sub> (δ<sub>H</sub> 7.16, 7.14) to Dhb-C=O (δ<sub>C</sub> 165.8) and Dhb-Cα (δ<sub>C</sub> 130.5), from Dhb-Hβ (δ<sub>H</sub> 6.47) to




Fig. 1 Chemical structure of **1**.

<sup>a</sup>China Pharmaceutical Culture Collection, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People's Republic of China. E-mail: zhangdewu@163.com; jly@cpcc.ac.cn

<sup>b</sup>Division for Medicinal Microorganisms Related Strains, CAMS Collection Center of Pathogenic Microorganisms, Beijing 100050, People's Republic of China

† Electronic supplementary information (ESI) available: HRESIMS, UV, ECD, Marfey's analyse, 1D and 2D NMR for **1**. See DOI: <https://doi.org/10.1039/d4ra01496k>

‡ These authors have contributed equally to this work.



**Table 1**  $^1\text{H}$  NMR (600 MHz) and  $^{13}\text{C}$  NMR (150 MHz) data of **1** in DMSO- $d_6$ 


Unit	No.	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ (J in Hz)
Dhb	NH		9.34, s
	CO	165.8, C	
	$\alpha$	130.5, C	
	$\beta$	129.0, CH	6.47, q (6.6)
	$\gamma$	13.3, $\text{CH}_3$	1.63, d (6.6)
	$\text{NH}_2$		7.16, s
Thr			7.14, s
	NH		8.24, d (7.2)
	OH		5.52, br s
	CO	168.7, C	
	$\alpha$	58.8, CH	4.50, dd (7.2, 4.2)
	$\beta$	66.8, CH	4.20, m
Thz	$\gamma$	19.8, $\text{CH}_3$	1.19, d (6.6)
	CO	160.1, C	
	2	160.1, C	
	4	150.3, C	
Pyr	5	128.5, CH	8.70, s
	2	150.5, C	
	3	128.4, C	
	4	139.8, CH	8.86, d (8.4)
	5	125.8, CH	8.50, d (8.4)
	6	134.1, C	
	7	160.0, C	
	8	116.6, C	
Dha	NH		10.44, s
	CO	164.8, C	
	$\alpha$	133.5, C	
	$\beta$	103.4, $\text{CH}_2$	6.57, s
			5.86, s
	$\text{NH}_2$		8.20, s
			7.74, s


Dhb-C=O ( $\delta_{\text{C}}$  165.8), Dhb-C $\alpha$  ( $\delta_{\text{C}}$  130.5), and Dhb-C $\gamma$  ( $\delta_{\text{C}}$  13.3) revealed the presence of dehydrobutyrine group. The HMBC correlations from Thr-H $\gamma$  ( $\delta_{\text{H}}$  1.19) to Thr-C $\alpha$  ( $\delta_{\text{C}}$  58.8) and Thr-C $\beta$  ( $\delta_{\text{C}}$  66.8), from Thr-H $\alpha$  ( $\delta_{\text{H}}$  4.50) to Thr-C=O ( $\delta_{\text{C}}$  168.7), Thr-C $\beta$  ( $\delta_{\text{C}}$  66.8), Thr-C $\gamma$  ( $\delta_{\text{C}}$  19.8), and Thz-C=O ( $\delta_{\text{C}}$  160.1), along with the  $^1\text{H}$ - $^1\text{H}$  COSY correlations of Thr-NH ( $\delta_{\text{H}}$  8.24)/Thr-H $\alpha$  ( $\delta_{\text{H}}$  4.50)/Thr-H $\beta$  ( $\delta_{\text{H}}$  4.20)/Thr-H $\gamma$  ( $\delta_{\text{H}}$  1.19) indicated the presence of threonine moiety. The HMBC correlations from Thz-H-5 ( $\delta_{\text{H}}$  8.70) to Thz-C=O ( $\delta_{\text{C}}$  160.1), Thz-C-2 ( $\delta_{\text{C}}$  160.1), and Thz-C-4 ( $\delta_{\text{C}}$  150.3) and typical chemical shifts of Thz-C-2 ( $\delta_{\text{C}}$  160.1), Thz-C-4 ( $\delta_{\text{C}}$  150.3), and Thz-C-5 ( $\delta_{\text{C}}$  128.5) for thiazole unit in thiopeptide derivative established the presence of thiazole group. The HMBC cross peaks from Pyr-H-4 ( $\delta_{\text{H}}$  8.86) to Pyr-C-2 ( $\delta_{\text{C}}$  150.5), Pyr-C-3 ( $\delta_{\text{C}}$  128.3), and Thz-C-2 ( $\delta_{\text{C}}$  160.1), from Pyr-H-5 ( $\delta_{\text{H}}$  8.50) to Pyr-C-6 ( $\delta_{\text{C}}$  134.1) and Pyr-C-7 ( $\delta_{\text{C}}$  160.0), together with the  $^1\text{H}$ - $^1\text{H}$  COSY correlations for Pyr-H-4 ( $\delta_{\text{H}}$  8.86)/Pyr-H-5 ( $\delta_{\text{H}}$  8.50) determined the presence of 2,3,6-trisubstituted pyridine group. The HMBC correlations from Dha-H $\beta$  ( $\delta_{\text{H}}$  6.57, 5.86) to Dha-C=O ( $\delta_{\text{C}}$  164.7) and Dha-C $\alpha$  ( $\delta_{\text{C}}$  133.5), from terminal -NH $_2$  ( $\delta_{\text{H}}$  8.20, 7.74) to Dha-C=O ( $\delta_{\text{C}}$  164.7) and Dha-C $\alpha$  ( $\delta_{\text{C}}$  133.5) indicated the presence of dehydroalanine residue. The critical HMBC correlations from Dhb-NH ( $\delta_{\text{H}}$  9.34) to Dhb-C $\beta$  ( $\delta_{\text{C}}$  129.0) and Thr-C=O ( $\delta_{\text{C}}$  168.7), from Thr-NH ( $\delta_{\text{H}}$  8.24) to Thr-

C=O ( $\delta_{\text{C}}$  168.7), Thr-C $\alpha$  ( $\delta_{\text{C}}$  58.8), Thr-C $\beta$  ( $\delta_{\text{C}}$  66.8), and Thz-C=O ( $\delta_{\text{C}}$  160.1), from Dha-NH ( $\delta_{\text{H}}$  10.44) to Dha-C=O ( $\delta_{\text{C}}$  164.7), Dha-C $\beta$  ( $\delta_{\text{C}}$  103.4), and Pyr-C-7 ( $\delta_{\text{C}}$  160.0) established the linkage of each residue. Furthermore, the long-range correlations (four bond) in HMBC spectrum from Pyr-H-4 ( $\delta_{\text{H}}$  8.86) to Pyr-C-8 ( $\delta_{\text{C}}$  116.6), along with the molecular formula and chemical shift of Pyr-C-8 suggested the existence of nitrile group. Based on the above observations, the planar structure of **1** was determined to be an unusual thiopeptide with nitrile moiety. The NOESY correlation (Fig. 2) between methyl protons ( $\delta_{\text{H}}$  1.63) and amide proton ( $\delta_{\text{H}}$  9.34) indicated the *Z* configuration of methyl-substituted double bond in dehydrobutyrine residue. The configuration of Thr was established as *L* using Marfey's method (Fig. S1†).<sup>11</sup>

Nitrile-containing natural products produced by microorganisms are relatively rare and the biosynthesis routes to form nitriles are also rarely reported in the literature. To the best of our knowledge, bernitrilecin (**1**) represents the first example of thiopeptide bearing nitrile group. The biosynthesis of **1** is proposed to be through classical thiopeptide biosynthetic pathway combined with special oxidation reactions (Scheme 1). Two linear peptide residues **a** and **b** take part in the pyridine-forming event to produce the linear thiopeptide scaffold (**c**), and the subsequent oxidation give carboxyl intermediate (**d**). The intermediate **d** undergoes decarboxylation to make amino intermediate (**e**), which can be converted to *N,N*-dihydroxyamine intermediate (**f**), and further dehydration lead to the formation of **1** featuring nitrile moiety. We speculate that cytochrome P450 enzyme might play a critical role in the conversion of amino to nitrile, as of examples, similar enzymic catalytic reactions can be found in the biosynthesis of dhurrian and borrelidin.<sup>12,13</sup>

Compound **1** was evaluated for anti-influenza A virus (IAV) and antibacterial activities.<sup>13</sup> Compound **1** displayed significant anti-IAV (H1N1) activities with the IC<sub>50</sub> value of 16.7  $\mu\text{M}$ . Compound **1** was also tested for antibacterial activities against *Staphylococcus aureus* ATCC 29213, *Escherichia coli* ATCC 25922, *Enterococcus faecalis* ATCC 29212, *Pseudomonas syringae* CPCC 101099, and *Bacillus cereus* CPCC 101254. Compound **1** showed no antimicrobial activity against all pathogenic bacteria with MIC >32  $\mu\text{g mL}^{-1}$ .

**Fig. 2** Key COSY, HMBC and NOESY correlations of **1**.



Scheme 1 Proposed biosynthetic pathway of 1.

## Conclusions

In summary, a new linear thiopeptide, bernitrilecin (**1**) was isolated from *Streptomyces* sp. CPCC 203702. Compound **1** was unusual oligomeric linear thiopeptide with nitrile group. Compound **1** showed significant anti-IAV activity.

## Experimental

### General experimental procedures

Optical rotations were recorded on an Autopol IV automatic polarimeter. The CD spectra were measured on a JASCO J-815 spectropolarimeter. UV spectra were obtained on a Persee TU-1901 UV-vis spectrometer. 1D and 2D NMR spectra were performed at 600 MHz for  $^1\text{H}$  NMR and 150 MHz for  $^{13}\text{C}$  NMR on Bruker ARX-600 spectrometer. Chemical shifts ( $\delta$ ) are given in ppm, and coupling constants ( $J$ ) are given in hertz (Hz). ESIMS data were recorded on a Thermo LTQ mass spectrometer. HRESIMS data were measured using a Thermo LTQ Orbitrap XL mass spectrometer. Column chromatography (CC) were carried out with silica gel (200–300 mesh, Qingdao Marine Chemical Inc. Qingdao, PR China). Analytical TLC was carried out on pre-coated silica gel GF<sub>254</sub> plates (Qingdao Marine Chemical Industry, Qingdao, China), and spots were visualized under UV light.

### Biological material

The strain *Streptomyces* sp. CPCC 203702 was isolated from the soil, collected in Xunhua County, Qinghai Province, China. The strain was identified as a member of the genus *Streptomyces* on the basis of 16S rRNA gene sequence analysis by China Pharmaceutical Culture Collection. A BLAST search displayed that

the sequence was the same (100%) as the sequence of *Streptomyces atroolivaceus* NRRL ISP-5137(T).

### Fermentation, extraction and isolation

Strain CPCC 203702 was spread onto slants of ISP2 medium and incubated at 28 °C for 8–10 days. Fresh spores of the strain was inoculated into 500 mL Erlenmeyer flasks containing 100 mL of sterile fermentation medium (glucose 0.5%, malt extract 1.0%, cotton seed meal 1.0%, amylogon 2.0%, yeast extract 0.5%,  $\text{K}_2\text{HPO}_4$  0.05%,  $(\text{NH}_4)_2\text{SO}_4$  0.5%,  $\text{CaCO}_3$  0.3%, NaCl 0.1%) at 28 °C on a rotary shaker (200 rpm) for 48 hours to prepare the seed culture. Then 2 L of seed culture was transferred into 20 L fermentor containing the same medium and cultured at 28 °C for 4 days.

The cultures (20 L) were filtered under reduced pressure to afford the filtrate and mycelia. The mycelia was extracted with EtOAc three times. The EtOAc extract was evaporated under reduced pressure to yield 20 g of residue, which was subjected to silica gel CC eluting with a chloroform–acetone gradient (100 : 0–0 : 100) to produce twenty-one fractions (Fr.1–Fr.21) on the basis of TLC analysis. Fraction Fr.18 (111 mg) was subjected to Sephadex LH-20 CC to give seven fractions (Fr.18.1–Fr.18.7), fraction Fr.18.4 (10.2 mg) was further isolated by reversed-phase preparative HPLC eluting with  $\text{CH}_3\text{CN}$ – $\text{H}_2\text{O}$  (10 : 90) at 4 mL min<sup>−1</sup> to give **1** (1.1 mg).

Bernitrilecin (**1**): white amorphous powder;  $[\alpha]_D^{25} +85.6$  ( $c$  0.03, MeOH); UV (MeOH)  $\lambda_{\text{max}}$ : 207, 314; CD (MeOH)  $\Delta\epsilon$  (nm): −4.75 (213), +7.69 (245), +1.15 (313); ESIMS  $m/z$  527.2  $[\text{M} + \text{H}]^+$ ; HRESIMS  $m/z$  527.1451  $[\text{M} + \text{H}]^+$  (calcd for  $\text{C}_{22}\text{H}_{23}\text{N}_8\text{O}_6\text{S}$ , 527.1461);  $^1\text{H}$  and  $^{13}\text{C}$  NMR data, see Table 1.

### C<sub>3</sub> Marfey's analysis

Approximately 0.1 mg of object was hydrolyzed with 0.2 mL of 6 mol L<sup>−1</sup> HCl and heated at 90 °C for 12 h. After removing the



solvent under reduced pressure, the hydrolysate was dissolved in 50  $\mu\text{L}$  of  $\text{H}_2\text{O}$ , and then 50  $\mu\text{L}$  of L-FDAA (1% solution in acetone) and 20  $\mu\text{L}$  of 1 mol  $\text{L}^{-1}$   $\text{NaHCO}_3$  were added to the mixture. The reaction mixture was heated for 1 h at 40  $^\circ\text{C}$ , cooled to room temperature, neutralized with 20  $\mu\text{L}$  of 1 mol  $\text{L}^{-1}$   $\text{HCl}$ , and then diluted with 500  $\mu\text{L}$   $\text{MeCN}$ . The FDAA derivatives were subjected to HPLC-DAD-MS analysis (Agilent Zorbax SB-C<sub>3</sub> column, 5  $\mu\text{m}$ , 250  $\times$  4.6 mm, 30  $^\circ\text{C}$ , 1 mL  $\text{min}^{-1}$ , linear gradient elution from 10% to 60%  $\text{MeCN-H}_2\text{O}$  (0.1% formic acid) in 50 min, UV detection at 340 nm).

### Anti-IAV activity assays

Bernitrilecin (1) was evaluated for anti-IAV activity as previously described methods.<sup>11</sup>

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The work was financially supported by the National Natural Science Foundation of China (82073744), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-055), and the National Microbial Resource Center (No. NMRC-2023-3).

## Notes and references

- 1 X. Shen, M. Mustanfa, Y. Chen, Y. Gao and J. Gao, *Med. Chem. Res.*, 2019, **28**, 1063–1098.

- 2 M. C. Bagley, J. W. Dale, E. A. Merritt and X. Xiong, *Chem. Rev.*, 2005, **105**, 685–714.
- 3 A. A. Vinogradov and H. Suga, *Cell Chem. Biol.*, 2020, **27**, 1032–1051.
- 4 A. Rouf and C. Tanyeli, *Eur. J. Med. Chem.*, 2015, **97**, 911–927.
- 5 D. C. K. Chan and L. L. Burrows, *J. Antibiot.*, 2021, **74**, 161–175.
- 6 Y. B. Hsu, M. C. Lan, Y. L. Kuo, C. Y. F. Huang and M. Y. Lan, *Invest. New Drugs*, 2020, **38**, 264–273.
- 7 A. A. Vinogradov, Y. Zhang, K. Hamada, J. S. Chang, C. Okada, H. Nishimura, N. Terasaka, Y. Goto, K. Ogata, T. Sengoku, H. Onaka and H. Suga, *J. Am. Chem. Soc.*, 2022, **144**, 20332–20341.
- 8 W. Peng, Z. Hong, X. Chen, H. Gao, Z. Dai, J. Zhao, W. Liu, D. Li and K. Deng, *Antimicrob. Agents Chemother.*, 2020, **64**, 023288.
- 9 Y. Wang, W. Xie, J. Humeau, G. Chen, P. Liu, J. Pol, Z. Zhang, O. Kepp and G. Kroemer, *J. Immunother. Cancer*, 2020, **8**, e000462.
- 10 C. Bailly, *Eur. J. Pharmacol.*, 2022, **914**, 174661.
- 11 D. Zhang, Y. Wang, X. Hu, X. Wang, L. Li, G. Gu, B. Zhang, S. Cen, X. You and L. Yu, *Chin. J. Chem.*, 2021, **39**, 3277–3284.
- 12 R. A. Kahn, T. Fahrendorf, B. A. Halkier and B. L. Møller, *Arch. Biochem. Biophys.*, 1999, **363**, 9–18.
- 13 C. Olano, S. J. Moss, A. F. Braña, R. M. Sheridan, V. Math, A. J. Weston, C. Méndez, P. F. Leadlay, B. Wilkinson and J. A. Salas, *Mol. Microbiol.*, 2004, **52**, 1745–1756.

